Vaccine Reaction
Conditions
Brief summary
The purpose of the study is to evaluate innate and adaptive immunity following QIV-HD vaccination compared to QIV-SD vaccination in people 65 years of age and older.
Detailed description
The hypothesis is that higher dose of antigen can increase the intensity and the quality of innate immunity, as the adaptive humoral and cellular responses. In this study, the objectif is to evaluate innate and adaptive immunity following QIV-HD vaccination compared to QIV-SD vaccination in people 65 years of age and older. Modifications of early blood molecular (transcriptome) and cellular (blood phenotyping) signatures within the first 24 hours following vaccination will be investigated. The association between early gene signature and late influenza-specific humoral immune responses weeks/months after vaccination will be also assessed. This study is a hase IV, randomized, open-label, active-controlled, multi-center study comparing the immune response induced by QIV-HD vaccine (intervention) and QIV-SD vaccine (control).
Interventions
BIOLOGICALExperimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)
Patient will received one dose of High Dose Quadrivalent Influenza Vaccine according to marketing authorization.
BIOLOGICALActive Comparator: Standard-Dose Quadrivalent Influenza Vaccine
Patient will received one dose of Standard Dose Quadrivalent Influenza Vaccine according to marketing authorization.
Sponsors
Sanofi Pasteur, a Sanofi Company
Euraxi Pharma
Hospices Civils de Lyon
Institut National de la Santé Et de la Recherche Médicale, France
Eurofins Optimed
Centre Hospitalier Annecy Genevois
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Aged 65 years or older, the day of inclusion; 2. Have signed and dated Informed Consent Form; 3. Able and willing to attend all scheduled visits, and to comply with study procedures; 4. Covered by French health insurance. Non-Inclusion Criteria : 1. Any vaccine injection (including COVID-19 vaccine) in the 4 weeks preceding study inclusion; 2. Plan to receive any vaccine (including COVID-19 vaccine) in the 4 weeks following study inclusion; 3. Already vaccinated against influenza for 2021-2022 season; 4. Hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances; 5. HIV infection; 6. Active Hepatitis B, or active Hepatitis C; 7. Previous Guillain Barré syndrome; 8. Ongoing immunosuppressive treatment or active immunodeficiency; 9. Receipt of immune globulins, blood or blood-derived products in the past 3 months; 10. Thrombocytopenia or bleeding disorder, receipt of anticoagulants contraindicating IM vaccination based on investigator's judgment; 11. Influenza-like illness symptoms, including COVID-19, within 4 weeks before study inclusion; 12. Personnes referred to in articles L1121-6 and L1121-8 of Public Health Code (persons deprived of liberty by judicial or administrative decision and persons subject to a legal protection measure: guardianship or curatorship).
Exclusion criteria
1. Any subject presenting with influenza-like illness symptoms, including COVID-19 between inclusion (visit 1) and randomization (visit 2); 2. Subject unable to attempt visit at Day 0 (visit 2) and Day 1 (visit 3); 3. Blood sample at Day 0 (visit 2) impossible to obtain; 4. Receipt of vaccine injection or equivalent between inclusion (visit 1) and randomization (visit 2), other than those allowed and planned in the study. This includes non-study dose of 2021-2022 influenza vaccine, blood-derived immune globulins, blood, or blood-derived products. 5. Any unexpected event relevant to the physician in charge, after discussion with the coordinating investigator and the sponsor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of Transcriptomic profiles | Change from Baseline Transcriptomic profiles at day after vaccine injection (Day 1) | Transcriptomic profiles of blood cells (microarrays) will be performed to measure early systemic innate immune response |
| Change of Innate cellular phenotyping | Change from Baseline Innate cellular phenotyping at day after vaccine injection (Day 1) | Innate cellular phenotyping will be performed using 36 surface markers deciphering lineage cells monocytes, neutrophils, NK, antigen-presenting cells. |
| Change of Gene signature | Change from Baseline Gene signature at day after vaccine injection (Day 1) | Study of the transcriptional profile of the blood cells by microarrays |
| Humoral immune responses | Day 0, Day 21, Day 90 and Day 210 time | HAI titers, Individual HAI titers ratio, Subjects with titers ≥ 40, Seroconversion |
Countries
France
Outcome results
None listed